Information Provided By:
Fly News Breaks for August 7, 2018
ACAD
Aug 7, 2018 | 07:24 EDT
Stifel analyst Paul Matteis initiated coverage of Acadia with a Hold rating and a $17 price target, stating that he believes a company update on the ongoing pimavanserin FDA safety review in the second of this year or early 2019 will remove an overhang. However, his estimates are "materially below consensus" in 2019 and he expect pimavanserin to "churn its way" to $594M in PDP revenue by 2022, which is also materially below sell-side expectations.
News For ACAD From the Last 2 Days
There are no results for your query ACAD